Exelixis and Catalent Collaborate on ADCs
20th August 2020
US drug discovery company Exelixis and compatriot CDMO Catalent are partnering to develop multiple antibody-drug conjugates (ADCs). Catalents’s Redwood Bioscience subsidiary will use its proprietary SMARTag site-specific bioconjugation technology to build ADCs using monoclonal antibodies from Exelixis’ preclinical pipeline.
In exchange for an upfront payment of $10 million, Exelixis has received an exclusive option to nominate up to a fixed number of targets using the SMARTag ADC platform over a three-year period.
The companies plan to advance the ADCs into preclinical development. Prior to filing an Investigational New Drug application, Exelixis may exercise an exclusive option for a worldwide license of the ADC program and continue clinical development and commercialization. It will also provide funding for R&D, and Catalent will be eligible for development and commercial milestones plus royalties on net sales of any product that is commercialized as part of the partnership.
“Our collaboration with Catalent – the fifth pipeline-enhancing agreement we’ve signed since 2018 – provides an attractive framework for identifying and advancing differentiated ADC product candidates with the potential to improve upon current ADC therapies,” said Peter Lamb, Executive Vice President, scientific strategy and Chief Scientific Officer at Exelixis. “We are looking forward to working with Catalent as we rapidly advance our mission to help cancer patients recover stronger and live longer.”
Mike Riley, Catalent Biologics’ region president, North America, added that the SMARTag platform has recently demonstrated promising results in the clinic, which he said highlighted its potential to create ADCs with significantly expanded therapeutic indices.
For more information visit www.chemanager-online.com/en